OACC · Oaktree Acquisition Corp. III Life Sciences
$10.78
+0.02 (+0.14%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$264.63M
Shares
24.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.77
Open$10.77
Day$10.75–10.77
52W close$10.46–10.80
Avg vol 30d60K
Short int1K · 0.0% float · 1.0d
Short vol0%
DataDec 2024–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$6.75M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
39.2
Trailing earnings · reciprocal yield 2.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+2.9%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+1%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
90%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+2%
trailing
YTD return
+2%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -85.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 1-yr range
Squeeze score
21
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
5%
annualized · 1-yr
Max drawdown
−3%
past year
ATR
0.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
90%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -85.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $10
Now $11 · 90%
Range high $11
vs 200-day avg +2%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OACC
this stock
Oaktree Acquisition Corp. III Life Sciences
|
$264.63M | +1.7% | — | — | 0.0% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$686.22M | — | — | — | 6.7% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$647.37M | +2.7% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$602.01M | +2.7% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OACC | +0.1% | +0.5% | +1.6% | +0.1% | +1.8% |
| SPY | -1.0% | -1.9% | +14.9% | -1.2% | +11.1% |
| vs SPY | +1.0% | +2.4% | -13.3% | +1.3% | -9.4% |